NanoString and Flow cytometer
Since 2017, support from Stichting Overleven met Alvleesklierkanker has enabled Erasmus MC to use NanoString technology to analyse DNA, RNA and protein profiles in diseases such as cancer. These detailed immune profiles can help researchers develop treatments tailored to individual patients. Transcriptomic techniques can improve the classification of disease and support a more personalised approach to therapy.
To purchase NanoString's nCounter FLEX Analysis System, the foundation entered into a loan agreement with Erasmus MC. In 2018, it also decided to purchase the company's then-new GeoMx Digital Spatial Profiler. Erasmus MC became one of the first 25 institutions worldwide to gain access to the instrument in 2019.
These expanded analytical capabilities provide more detailed information about the composition of tumours and the immune systems of people with pancreatic cancer. The aim is to develop better prognostic tests that can identify the most suitable treatment for each patient.
In 2025, Erasmus MC acquires a new spectral Flowcythometer, allowing even more detailed analysis of cell and tissue levels. In this way, a more complete picture can be formed of how the immune system looks and changes patients in pancreatic cancer and can be further optimized.
This flow cytometer was co-funded through the money raised for Support Casper by De Westlandse Ride in 2024.